BLR&D Research Career Scientist Award Application

BLR

• 批准号: 10293578
• 负责人: DIDIER MERLIN
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-10-01 至 2025-09-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10293578
• 关键词: Adult; Affect; Americas; Anti-Inflammatory Agents; Award; Cellular biology; Child; Colitis; Collaborations; Colorectal Cancer; Data; Development; Diagnosis; Digestive System Disorders; Discipline; Disease; Doctor of Philosophy; Environment; Etiology; Faculty; Focus Groups; Fostering; Foundations; Future; Gastroenterology; General Population; Grant; Healthcare; Inflammatory Bowel Diseases; Institutes; Interdisciplinary Study; Intestines; Journals; K-Series Research Career Programs; Laboratories; Medical center; Mission; Molecular Biology; Mucosal Immunity; Nanotechnology; Neurofibromin 2; Pathogenesis; Pathologic; Patients; Peptides; Physicians; Population; Publishing; Research; Research Personnel; Science; Scientist; Seminal; Series; Structure; Techniques; Training; Transcend; United States National Center for Health Statistics; Universities; Veterans; Work; base; career; clinical care; colitis associated cancer; gut inflammation; improved; indexing; interest; large bowel Crohn' s disease; lectures; meetings; member; military veteran; next generation; novel; novel therapeutic intervention; programs; symposium; training opportunity; treatment strategy

D. Merlin Ph.D, Summary Our research program is directed toward understanding the pathogenesis of intestinal inflammation and formulating treatment strategies for intestinal inflammatory diseases such as IBD. Our work has been published consistently in reputable journals and cited extensively (December 20, 2017: h-index of 45). Our laboratory is familiar with a vast number of techniques, from nanotechnology to molecular biology to cell biology. Over one million adults and children in the US, including members of the VA population, suffer from IBD, with about 50,000 new cases diagnosed each year, according to the Crohn’s and Colitis Foundation of America. VA IBD patients have a much higher rate of colorectal cancer compared to the general population (2.9% vs. 0.1%, according to the National Center for Health Statistics). New therapeutic strategies based on a better understanding of the pathogenesis of IBD will improve the clinical care of veteran and non-veteran patients with this disorder. We have long recognized the value of interdisciplinary research in furthering scientific discovery, as important research ideas often transcend the scope of a single discipline or program. In this context, we have promoted collaborative interdisciplinary research between scientists/physicians with interests in gastroenterology at the Atlanta VA Medical Center and scientists at the Institute for Biomedical Sciences of Georgia State University. These multidisciplinary collaborations are intended to develop novel ideas that will enhance the diagnosis and treatment of colitis and colitis-associated cancers that affect the VA population. 1

D. Merlin博士，摘要 我们的研究计划旨在理解肠道注射的发病机理 制定肠道炎症性疾病（例如IBD）的治疗策略。我们的作品已出版 在著名的期刊中始终引用并广泛引用（2017年12月20日：H-INDEX为45）。我们的实验室是 熟悉从纳米技术到分子生物学再到细胞生物学的大量技术。超过一个 美国的百万成人和儿童，包括VA人口的成员，患有IBD，约有50,000人 根据美国克罗恩斯和结肠炎基金会的说法，每年都会诊断出新病例。 VA IBD患者 与普通人群相比，结直肠癌的发生率要高得多（根据2.9％比0.1％ 国家卫生统计中心）。基于更好地理解的新治疗策略 IBD的发病机理将改善这种疾病的退伍军人和非退伍军人患者的临床护理。我们 长期以来已经认识到跨学科研究在进一步的科学发现中的价值，很重要 研究思想经常超越单一学科或计划的范围。在这种情况下，我们促进了 科学家/医师之间对胃肠病学兴趣的合作跨学科研究 佐治亚州立大学生物医学研究所的亚特兰大医学中心和科学家。 这些多学科合作旨在发展新颖的想法，以增强诊断和 治疗影响VA种群的结肠炎和结肠炎相关的癌症。 1